Quarterly ResultMay 12, 2026, 04:15 PM
Zentalis Q1 Net Loss $(35.35)M; Azenosertib Phase 3 Initiated
AI Summary
Zentalis Pharmaceuticals reported a net loss of $(35.35) million, or $(0.50) per share, for Q1 2026, an improvement from $(48.28) million in Q1 2025. The company ended the quarter with $211.8 million in cash, providing a runway into late 2027. Key clinical progress includes the selection of 400mg QD 5:2 as the pivotal dose for azenosertib monotherapy in Cyclin E1-positive platinum-resistant ovarian cancer (PROC) and the initiation of the ASPENOVA Phase 3 confirmatory trial. The DENALI Phase 2 trial's topline readout is expected by year-end 2026, potentially supporting accelerated approval.
Key Highlights
- Q1 2026 net loss was $(35.35) million, or $(0.50) per share, an improvement from $(48.28) million in Q1 2025.
- Cash, cash equivalents, and marketable securities totaled $211.8 million as of March 31, 2026.
- Company projects cash runway into late 2027, supporting key milestones.
- Azenosertib pivotal study dose of 400mg QD 5:2 selected for Cyclin E1-positive PROC.
- ASPENOVA Phase 3 confirmatory trial initiated with first patient dosed in Q2 2026.
- DENALI Phase 2 trial topline readout expected by year-end 2026 for potential accelerated approval.
- R&D expenses rose to $28.7 million in Q1 2026 from $27.2 million in Q1 2025.
- G&A expenses decreased to $9.1 million in Q1 2026 from $10.6 million in Q1 2025.